Is Eli Lilly (LLY) a Buy Right Now?
A plain-English read on Eli Lilly stock — what the chart and the numbers are saying today, with no jargon and no hype.
What this means, in plain English
Eli Lilly is currently trading at $1123.91, reflecting a 2.21% decline today. The RSI—a gauge of whether a stock has climbed too far or too fast—sits at 33.5. This suggests the stock is moving toward an oversold level, where selling pressure may be easing.
The price remains above the 200-day average of $1075.18, which is a common indicator of a long-term upward trend. While it sits below the 50-day average of $1185.86, the current price is comfortably above the recent support level, or floor, of $1113.55.
Should you buy Eli Lilly stock?
A buy rating here reflects the current technical support levels and the long-term trend. Investors should view this as a potential entry point rather than a guaranteed gain. Always consider your own risk tolerance before adding a large company like this to your portfolio.
Is LLY a good stock for beginners?
Eli Lilly is a massive, established pharmaceutical company, which often brings more stability than smaller, speculative stocks. However, all stocks experience volatility, or price swings, as seen by the 52-week range of $783.85 to $1292.65. Beginners should focus on the long-term trend rather than daily movements.
What's driving LLY right now
The current price of $1123.91 is holding steady above the recent support level of $1113.55.
The stock remains in an upward trend by staying above its 200-day average of $1075.18.
An RSI of 33.5 indicates the stock is cooling off from previous highs.
The price currently sits below the 50-day average of $1185.86.
What Eli Lilly actually does
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Who owns Eli Lilly?
Institutions — pension funds, asset managers, index providers — hold 85.4% of LLY, and the concentration matters: the largest single holder alone controls 9.60% of the company.
| Holder | Shares | % held |
|---|---|---|
| 90.38M | 9.60% | |
| 67.54M | 7.17% | |
| 53.53M | 5.69% |
Names withheld — plus 3 more records not shown.
See who owns itWhat Eli Lilly insiders have been doing
Executives and directors must disclose their own trades in company stock. Of the last 6 disclosed transactions we hold for Eli Lilly, 2 were sales and 0 were open-market purchases; the other 4 were awards, vesting or option exercises rather than a decision to buy or sell. Insiders sell for many ordinary reasons — scheduled plans, tax, diversification — so a sale is not by itself a signal.
| Insider | Date | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-17 | AWARD / VEST | 13 | $15.9K | |
| 2026-08-17 | AWARD / VEST | 4 | $5.0K | |
| 2026-08-17 | SELL | 6.5K | $7.6M |
Names withheld — plus 3 more records not shown.
See which insidersThe numbers behind the read
Who in Washington has been trading LLY?
Members of Congress must disclose trades over $1,000 within 45 days under the STOCK Act. At least 25 disclosures name LLY — filed by 9 separate members or more and worth $102K–$530K combined (filings report bands, never exact amounts). 8 purchase-side, 17 sale-side, most recently on 2026-07-10.
| Member | Date | Action | Amount filed |
|---|---|---|---|
| 2026-07-10 | SELL | $1,001 - $15,000 | |
| 2026-07-01 | SELL | $1,001 - $15,000 | |
| 2026-06-10 | BUY | $50,001 - $100,000 |
Names withheld — plus 22 more records not shown.
See which membersWith the price resting near support and the trend remaining positive, Eli Lilly presents a logical buy for those building a long-term portfolio.
Don't guess. Practice this trade first.
Buy it with virtual cash and watch how it plays out — before a dollar of your own is on the line.
Practice LLY risk-free in your paper portfolioPaper trading, the AI Read & live indicators are inside a Money GPS membership — one price, the whole platform.
Beginner questions about LLY
Should I buy LLY stock?+
Based on the current technical setup and the price holding above its 200-day average, the data supports a buy position.
Is LLY a good long-term investment?+
The long-term trend remains positive as the price stays above the $1075.18 average, though you must weigh this against the 52-week price range.
Is LLY a buy or a sell?+
The data indicates a buy, as the price is currently supported near $1113.55 and shows an RSI of 33.5.
Is LLY overvalued?+
With a P/E ratio of 23.8, investors must decide if the valuation fits their strategy relative to the 52-week high of $1292.65.
Is LLY a good stock for beginners?+
As a large, established company, it may suit beginners, but one should be prepared for the volatility shown by the $783.85 to $1292.65 range.
Important disclaimer
This page is for educational and informational purposes only and is not financial, investment, tax, or legal advice, nor a recommendation, offer, or solicitation to buy, sell, or hold Eli Lilly (LLY) or any other security. The Money GPS is not a registered investment adviser, broker-dealer, or financial planner, and no content here should be relied upon to make an investment decision.
The verdict, indicators, and commentary are generated automatically — in part using AI — from third-party market data (via Yahoo Finance) that may be delayed, incomplete, or inaccurate, and is provided “as is” without any warranty. Figures reflect the market as of 2026-09-08 and change constantly; the read above may already be out of date. A “Buy,” “Hold,” or “Be Careful” label is a simplified, rules-based signal for beginners — not a price target or a guarantee of any outcome.
All investing involves risk, including the possible loss of your entire principal. Past performance and historical patterns do not guarantee future results. Always do your own research and consult a licensed financial professional who knows your personal circumstances before investing. You are solely responsible for your own investment decisions. The Money GPS and its authors may hold positions in the securities discussed and accept no liability for any loss arising from the use of this information.